Patents Assigned to Health Corporation
-
Patent number: 10716310Abstract: A process for inhibiting foodborne pathogens and reducing foodborne disease involves contacting a living animal, a dressed carcass, or a cut of meat with an effective amount of a bacillus strain exhibiting antibacterial activity. Strains of antibacterial bacillus that are particularly effective for inhibiting Vibrio were discovered. These include Bacillus licheniformis OBT 712 and Bacillus amyloliquefaciens OBT 618.Type: GrantFiled: March 13, 2014Date of Patent: July 21, 2020Assignee: Phibro Animal Health CorporationInventors: Christopher J. Reuter, Steven J. MacKenzie, Lauren G. Danielson, Vincent Scuilla
-
Publication number: 20200178548Abstract: A process for inhibiting foodborne pathogens and reducing foodborne disease involves contacting a living animal, a dressed carcass, or a cut of meat with an effective amount of a bacillus strain exhibiting antibacterial activity. Strains of antibacterial bacillus that are particularly effective for inhibiting Vibrio were discovered. These include Bacillus licheniformis OBT 618 and Bacillus amyloliquefaciens OBT 712.Type: ApplicationFiled: February 21, 2020Publication date: June 11, 2020Applicant: Phibro Animal Health CorporationInventors: Christopher J. Reuter, Steven J. MacKenzie, Lauren G. Danielson, Vincent Scuilla
-
Patent number: 10660930Abstract: The present disclosure concerns embodiments of a combination and/or composition comprising bacillus, and yucca, quillaja or both. Embodiments of methods of making and using the combination and/or composition also are disclosed herein. In some embodiments, the combination and/or composition may be used to improve feed conversion rates in animals. In some embodiments the animals are avians; in other embodiments, the animals are non-avians. Embodiments of the disclosed combination can comprise a first composition comprising Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans. Embodiments of the disclosed composition can comprise Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans.Type: GrantFiled: May 11, 2018Date of Patent: May 26, 2020Assignees: Phibro Animal Health Corporation, Desert King International LLCInventors: David Calabotta, Wendell Knehans, Derek McLean
-
Patent number: 10653151Abstract: A composition useful for application to plants, seeds or soil to inhibit fungal infections comprises a protein source inoculated with from 5×107 cfu to 5×109 cfu of a Bacillus amyloliquefaciens strain per gram of the protein source.Type: GrantFiled: February 1, 2018Date of Patent: May 19, 2020Assignee: Phibro Animal Health CorporationInventors: Christopher J. Reuter, Steven J. MacKenzie
-
Publication number: 20200054631Abstract: Disclosed compositions comprise a therapeutic agent and a carrier selected, or processed to have, an acceptable composite flow index, a granular particle size of 18 mesh to 80 mesh, or both, such as processed granular wheat middlings. The composition may also comprise an oil and/or micro tracers. Suitable granular wheat middlings may have a size range of from 18 mesh to 80 mesh, such as 20 mesh to 80 mesh. The composition has improved flowability characteristics, compared to a composition where the carrier, such as processed wheat middlings, are powdered and/or flakey. Certain embodiments concern a composition comprising, consisting essentially of, or consisting of, nicarbazin, granular wheat middlings, soybean oil and micro tracers. The composition may be administered to an animal, for example, to treat or prevent coccidiosis. Also disclosed herein are methods for making and using the composition.Type: ApplicationFiled: October 28, 2019Publication date: February 20, 2020Applicant: Phibro Animal Health CorporationInventors: Ian John Wilkinson, Charles Hollett Fahrenholz
-
Publication number: 20190350998Abstract: Disclosed herein are embodiments of a combination and/or composition for administration to animals. In some embodiments, the combination and/or composition can be administered to treat and/or prevent a disease in animals. In some embodiments, the combination and/or composition can be administered to promote animal health. In some embodiments, the combination comprises a composition comprising Yucca schidigera, Quillaja saponaria, and combinations thereof and a composition comprising an antimicrobial, an antibiotic, an anticoccidial, a vaccine, or combinations thereof. The combinations or compositions disclosed herein can also improve feed conversion rates in animals.Type: ApplicationFiled: July 29, 2019Publication date: November 21, 2019Applicants: Phibro Animal Health Corporation, Desert King International LLCInventors: Kenneth W. Bafundo, A. Bruce Johnson, David Calabotta, Wendell Knehans
-
Patent number: 10413581Abstract: Disclosed herein are embodiments of a combination and/or composition for administration to animals. In some embodiments, the combination and/or composition can be administered to treat and/or prevent a disease in animals. In some embodiments, the combination and/or composition can be administered to promote animal health. In some embodiments, the combination comprises a composition comprising Yucca schidigera, Quillaja saponaria, and combinations thereof and a composition comprising an antimicrobial, an antibiotic, an anticoccidial, a vaccine, or combinations thereof. The combinations or compositions disclosed herein can also improve feed conversion rates in animals.Type: GrantFiled: November 22, 2016Date of Patent: September 17, 2019Assignees: Phibro Animal Health Corporation, Desert King International LLCInventors: Kenneth W. Bafundo, A. Bruce Johnson, David Calabotta, Wendell Knehans
-
Publication number: 20190247490Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: ApplicationFiled: April 17, 2019Publication date: August 15, 2019Applicant: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Publication number: 20190231864Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: ApplicationFiled: March 14, 2019Publication date: August 1, 2019Applicant: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Publication number: 20190202868Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.Type: ApplicationFiled: March 15, 2019Publication date: July 4, 2019Applicant: Phibro Animal Health CorporationInventor: Byoung-Kwan Kim
-
Patent number: 10280199Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.Type: GrantFiled: August 4, 2016Date of Patent: May 7, 2019Assignee: Phibro Animal Health CorporationInventor: Byoung-Kwan Kim
-
Patent number: 10279031Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: GrantFiled: May 11, 2017Date of Patent: May 7, 2019Assignee: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Publication number: 20180256667Abstract: The present disclosure concerns embodiments of a combination and/or composition comprising bacillus, and yucca, quillaja or both. Embodiments of methods of making and using the combination and/or composition also are disclosed herein. In some embodiments, the combination and/or composition may be used to improve feed conversion rates in animals. In some embodiments the animals are avians; in other embodiments, the animals are non-avians. Embodiments of the disclosed combination can comprise a first composition comprising Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans. Embodiments of the disclosed composition can comprise Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans.Type: ApplicationFiled: May 11, 2018Publication date: September 13, 2018Applicants: Phibro Animal Health Corporation, Desert King International, LLCInventors: David Calabotta, Wendell Knehans, Derek McLean
-
Patent number: 9999648Abstract: The present disclosure concerns embodiments of a combination and/or composition comprising bacillus, and yucca, quillaja or both. Embodiments of methods of making and using the combination and/or composition also are disclosed herein. In some embodiments, the combination and/or composition may be used to improve feed conversion rates in animals. In some embodiments the animals are avians; in other embodiments, the animals are non-avians. Embodiments of the disclosed combination can comprise a first composition comprising Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans. Embodiments of the disclosed composition can comprise Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans.Type: GrantFiled: April 29, 2015Date of Patent: June 19, 2018Assignees: Phibro Animal Health Corporation, Desert King International, LLCInventors: David Calabotta, Wendell Knehans, Derek McLean
-
Publication number: 20180039737Abstract: A system and method that facilitates the automated replication of electronic medical record information between a patient and a health-care provider (HCP), such as a doctor, pharmacy, drug manufacturer, biologic manufacturer, or medical device manufacturer. The system uses: a cloud-based infrastructure that includes databases, mathematical models, and configuration information; a patient's electronic health record system providing personal data around a patient's individual personal electronic health record (PEHR); and a server used to coordinate and authenticate the replication of data between the cloud-based infrastructure, the PEHR, and the EHR system, of the HCP. The system provides support for mobile platforms and web-based platforms and sophisticated mechanisms for the transmission of data between these systems.Type: ApplicationFiled: November 17, 2016Publication date: February 8, 2018Applicant: UMBRA HEALTH CORPORATIONInventors: Ramon Dempers, Ophir FRIEDER
-
Publication number: 20170360586Abstract: An orthopedic support and/or treatment system including a brace or sleeve comprising a power subsystem; a sensor subsystem; an adjustment mechanism; a software subsystem; a communication subsystem; and a telemedicine subsystem. The orthopedic treatment system includes and communicates over a network to a remote controlling device. The remote control device can be a computer, a mobile device, or any other controller. The sensor subsystem communicates to the remote control device, which in turn can be used to control the adjustment mechanism to adjust a tension or compression of the brace or sleeve.Type: ApplicationFiled: June 12, 2017Publication date: December 21, 2017Applicant: UMBRA HEALTH CORPORATIONInventors: Ramon Dempers, Ophir FRIEDER
-
Publication number: 20170340729Abstract: Disclosed herein are embodiments of an immunogenic composition for porcine epidemic diarrhea virus, and a method for making the immunogenic composition. Also disclosed is a method for administrating the immunogenic composition to a subject in need thereof. The immunogenic composition comprises PEDV proteins and/or antigens from one or more strains of PEDV, and may additionally comprise proteins and/or antigens from one or more additional porcine pathogens, such as PRRSV. Additionally disclosed in a combination comprising a PEDV immunogenic composition as disclosed herein, and an immunogenic composition or other therapeutic composition directed toward an additional porcine pathogen.Type: ApplicationFiled: August 8, 2017Publication date: November 30, 2017Applicants: MJ Biologics, Inc., Phibro Animal Health CorporationInventors: Byoung-Kwan Kim, Karen Brown, Larry Miller
-
Publication number: 20170326226Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: ApplicationFiled: May 11, 2017Publication date: November 16, 2017Applicant: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Publication number: 20170072002Abstract: Disclosed herein are embodiments of a combination and/or composition for administration to animals. In some embodiments, the combination and/or composition can be administered to treat and/or prevent a disease in animals. In some embodiments, the combination and/or composition can be administered to promote animal health. In some embodiments, the combination comprises a composition comprising Yucca schidigera, Quillaja saponaria, and combinations thereof and a composition comprising an antimicrobial, an antibiotic, an anticoccidial, a vaccine, or combinations thereof. The combinations or compositions disclosed herein can also improve feed conversion rates in animals.Type: ApplicationFiled: November 22, 2016Publication date: March 16, 2017Applicants: Phibro Animal Health Corporation, Desert King International LLCInventors: Kenneth W. Bafundo, A. Bruce Johnson, David Calabotta, Wendell Knehans
-
Publication number: 20170076045Abstract: A method including sensing local accelerations or changes in sensor position, including orientation and displacement, with a local acceleration sensor mounted on a chest or abdomen of a patient, and calculating energy of polyphasic motions, based on sensed information of the local acceleration sensor and classifying severity of cardiac decompensation by calculating an excessive energy index (EEi) that compares excessive energy that appears in the polyphasic motions to energy required for inspiration at a basic respiratory rate.Type: ApplicationFiled: February 27, 2015Publication date: March 16, 2017Applicants: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD., RAMBAM HEALTH CORPORATIONInventors: Amir LANDESBERG, Yaakov ZIBOLI, Shmuel RISPLER